MiR-22 Enhances the Radiosensitivity of Small-cell Lung Cancer by Targeting the WRNIP1
Overview
Cell Biology
Affiliations
Small-cell lung cancer (SCLC) is an aggressive malignancy characterized by high cellular proliferation and early distant metastasis. Our study aimed to explore the effect of miR-22-3p (miR-22, for short) on SCLC radiosensitivity and its molecular mechanisms. The expression level of miR-22 was evaluated in a human normal lung epithelial cell line and a human SCLC cell line, and cell apoptosis and migration were detected. The expression of the miR-22 direct target WRNIP1 mRNA and protein were explored. Five differentially expressed genes were detected. The miR-22 expression in NCI-H446 was significantly decreased, and miR-22 overexpression significantly promoted cell apoptosis. miR-22 overexpression could significantly inhibit the cell migration of SCLC cells, and miR-22 had a negative regulatory effect on WRNIP1 mRNA and protein levels. KLK8 was downregulated, and the messenger RNA (mRNA) of four other genes (PC, SCUBE1, STC1, and GPM6A) was upregulated mRNA in cells overexpressing miR-22, which was in accordance with the bioinformatics analysis. miR-22 could enhance the radiosensitivity of SCLC by targeting WRNIP1.
Mechanisms of GPM6A in Malignant Tumors.
Huang B, Li X Cancer Rep (Hoboken). 2025; 8(2):e70137.
PMID: 39957375 PMC: 11831008. DOI: 10.1002/cnr2.70137.
Targeting STK26 and ATG4B: miR-22-3p as a modulator of autophagy and tumor progression in HCC.
Li K, Bai Y, Wang J, Ren L, Mo A, Liu R Transl Oncol. 2024; 51:102214.
PMID: 39608212 PMC: 11635773. DOI: 10.1016/j.tranon.2024.102214.
Research Trends and Evolution in Radiogenomics (2005-2023): Bibliometric Analysis.
Wang M, Peng Y, Wang Y, Luo D Interact J Med Res. 2024; 13:e51347.
PMID: 38980713 PMC: 11267093. DOI: 10.2196/51347.
An innovative prognostic auxiliary for colon adenocarcinoma based on zinc finger protein genes.
Xu F, Sun J, Gu X, Zhou Q Transl Cancer Res. 2024; 13(4):1623-1641.
PMID: 38737696 PMC: 11082816. DOI: 10.21037/tcr-23-2158.
Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer.
Sarrett S, Rodriguez C, Delaney S, Hosny M, Sebastiano J, Santos-Coquillat A Mol Pharm. 2024; 21(3):1402-1413.
PMID: 38331430 PMC: 10915790. DOI: 10.1021/acs.molpharmaceut.3c01063.